Abstract:Background & aims: Assessment of recurrence risk after liver resection (LR) is critical in hepatocellular carcinoma (HCC), particularly with the advent of effective adjuvant therapy. The aim of this study was to analyze the clinical and pathological factors associated with recurrence, aggressive recurrence, and survival after LR. Method: We performed a retrospective study in which all single HCC (BCLC-0/A) patients treated with LR between February 2000 and November 2020 were included. The main clinical variables were recorded. Histological features were blindly evaluated by two independent pathologists. Aggressive recurrence was defined as those that exceeded the Milan criteria at 1st recurrence. Results: A total of 218 patients were included (30% BCLC 0 and 70% BCLC A), median (IQR) tumor size of 28 (19-42 mm). The prevalence of microvascular invasion and/or satellitosis (mVI/S) was 39%, with a kappa-index between both pathologists of 0.8. After a median follow-up of 49 (23-85) months, 61/218 (28%) patients died, 32/218 (15%) underwent liver transplantation, 127 (58%) developed HCC recurrence. The prevalence of aggressive recurrence was 35% (44/127 Milan-out, with 20 cases at advanced stage), and the 5-year survival rate was 81%. The presence of mVI/S was the only independent predictor of recurrence (hazard ratio [HR] 1.83, 95% CI 1.28-2.61, p <0.001), aggressive recurrence (HR 3.31, 95% CI 1.74-6.29, p <0.001) and mortality (HR 2.23, 95% CI 1.27-3.91, p = 0.005). The macrotrabecular-massive subtype was significantly associated with a higher prevalence of mVI/S, Edmonson Steiner grade III-IV, AFP values and vessels that encapsulate tumor clusters, but not with recurrence, aggressive recurrence, or overall survival. Conclusion: The presence of mVI/S was the only independent risk factor for aggressive recurrence and mortality. This has important implications for early-stage patient management, especially in the setting of adjuvant immunotherapy or ab initio LT. Impact and implications: Assessment of recurrence risk after liver resection is crucial in patients with hepatocellular carcinoma. Patients with a high risk of recurrence are candidates for liver transplantation as an ab initio indication or for the potential use of adjuvant therapy. Aggressive recurrences, defined as those exceeding the Milan criteria at first recurrence, have a significant impact on overall survival (OS). Fifty-eight percent of patients experienced hepatocellular carcinoma recurrence, with a prevalence of aggressive recurrence at the first occurrence standing at 35%. After a median follow-up of 49 (23-85) months, 61 (28%) patients died, and 32 (15%) underwent liver transplantation, resulting in a 5-year OS rate of 81%. Microvascular invasion and/or satellitosis was present in 39% of our cohort and was the only independent predictor of recurrence, aggressive recurrence, and OS on multivariate analysis. This is important as it could be used to guide therapeutic management.

Recurrence of hepatocellular carcinoma after liver transplantation: clinical patterns and hierarchy of salvage treatments

Relationship Between Clinicopathologic Features and Neoplasm Recurrence,prognosis in Hepatocellular Carcinoma after Liver Transplantation

Clonal Origin of Hepatocellular Carcinoma and Recurrence after Liver Transplantation

Liver Transplantation for Hepatocarcinoma: Results over Two Decades of a Transplantation Programme and Analysis of Factors Associated with Recurrence

Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience

[Recurrence and Metastasis of Hepatocellular Carcinoma after Liver Transplantation: Single Center Experiences].

O-2 EVALUATION OF RISK FACTORS AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION

Recurrence of Hepatocellular Carcinoma after Liver Transplantation: Recurrence Characteristics and Risk Factors.

Hepatocellular carcinoma recurrence after liver transplantation: Risk factors, screening and clinical presentation

Clinical Features of Recurrence after Hepatic Resection for Early-stage Hepatocellular Carcinoma and Long-term Survival Outcomes of Patients with Recurrence - A Multi-institutional Analysis Contained 1424 Cases

Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives

Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

[Multivariate Analysis of Recurrence of Hepatocellular Carcinoma after Liver Transplantation].

Tracking the Evolving Ecosystem of Recurrent Hepatocellular Carcinoma after Liver Transplantation

Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection

Current Strategies for Preventing the Recurrence of Hepatocellular Carcinoma after Liver Transplantation

Predictors of Post-Recurrence Survival in Hepatocellular Carcinoma Patients Following Liver Transplantation: Systematic Review and Meta-Analysis.

Hepatocellular Carcinoma Recurrence and Mortality Rate Post Liver Transplantation: Meta-Analysis and Systematic Review of Real-World Evidence

Incidence and Risk Factor of Hepatocellular Carcinoma Recurrence After Liver Transplant: Results From a Single Clinic.

Risk Factors, Patterns, and Outcomes of Late Recurrence after Liver Resection for Hepatocellular Carcinoma: A Multicenter Cohort Study in 734 Patients over 15 Years